| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
KRAS inhibitor-9 had a moderate binding affinity of -5.38, -5.41, and -3.97 kcal/mol for KRASG12D, KRAS G12C, and KRAS Q61H protein, respectively[1].
KRAS inhibitor-9 (0-100 μM) exhibits strong inhibition selectivity in NSCLC cells with IC50s for H2122, H358, and H460 cells ranging from 39.56 to 66.02 μM (at 72 hours)[1]. KRAS inhibitor-9 (0-100 μM; 24 hours) inhibits the production of GTP-KRAS in H2122, H358, and H460 cells[1]. KRAS inhibitor-9 (25-100 μM; 48 hours) prevents the downstream signaling pathway of KRAS from being activated[1]. KRAS inhibitor-9 (0-100 μM; 24-72 hours) causes apoptosis and cell cycle arrest in NSCLC[1]. |
|---|---|
| Cell Assay |
Cell Line: H2122 (KRAS G12C), H358 (KRAS G12C) and H460 (KRAS Q61H) cell lines
Concentration: 0, 25, 50, 100 μM Incubation Time: 24, 48, and 72 hours Result: Inhibited three NSCLC cell lines in a dose- and time-dependent manner, but not in normal lung fibroblast cell line CCD-19Lu. |
| References |
| Molecular Formula |
C13H9CLN2S2
|
|---|---|
| Molecular Weight |
292.806958913803
|
| Exact Mass |
291.99
|
| Elemental Analysis |
C, 53.33; H, 3.10; Cl, 12.11; N, 9.57; S, 21.90
|
| CAS # |
300809-71-6
|
| Appearance |
Solid powder
|
| SMILES |
C1=CC=C2C(=C1)N=C(S2)SC3=C(C=C(C=C3)N)Cl
|
| InChi Key |
DTSNLMOLTVGCGZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H9ClN2S2/c14-9-7-8(15)5-6-11(9)17-13-16-10-3-1-2-4-12(10)18-13/h1-7H,15H2
|
| Chemical Name |
4-(1,3-benzothiazol-2-ylsulfanyl)-3-chloroaniline
|
| Synonyms |
DUN 09716; DUN09716; DUN-09716
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~250 mg/mL (~853.8 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4152 mL | 17.0759 mL | 34.1518 mL | |
| 5 mM | 0.6830 mL | 3.4152 mL | 6.8304 mL | |
| 10 mM | 0.3415 mL | 1.7076 mL | 3.4152 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
